SCHEMBL6640887

SCHEMBL6640887

Nc1nccc(-c2cc(Br)ccc2OCc2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGPAT2 O15120 2/20 0.49
PRKACA P17612 3/20 0.46
CCNB2 O95067 2/20 0.46
CDK1 P06493 2/20 0.46
CCNB1 P14635 2/20 0.46
PRKACG P22612 2/20 0.46
PRKACB P22694 2/20 0.46
CSNK1A1 P48729 2/20 0.46
CSNK1D P48730 2/20 0.46
CSNK1E P49674 2/20 0.46
CLK1 P49759 2/20 0.46
GSK3B P49841 2/20 0.46
CSNK1G2 P78368 2/20 0.46
CDK5 Q00535 2/20 0.46
CDK5R1 Q15078 2/20 0.46
CCNB3 Q8WWL7 2/20 0.46
CSNK1G1 Q9HCP0 2/20 0.46
PDPK1 O15530 1/20 0.46
CYP1A1 P04798 1/20 0.46
CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28509535 0.84 LTA4H (0.53) PRKACACSNK1A1CSNK1DCSNK1G2CSNK1G1
SCHEMBL30507524 0.84 LTA4H (0.53) PRKACACSNK1A1CSNK1DCSNK1G2CSNK1G1
SCHEMBL4282091 0.83 AGPAT2 (0.53) AGPAT2CCR5HSP90AA1PTGER1SLC6A4
SCHEMBL6638721 0.81 FEN1 (0.48) PRKACASMN1; SMN2AURKAHSP90AA1ADORA2A
SCHEMBL28286296 0.80 CCR5 (0.55) CCR5HTTSMN1; SMN2ALDH1A1LRRK2
SCHEMBL30835001 0.80 CCR5 (0.55) CCR5HTTSMN1; SMN2ALDH1A1LRRK2
SCHEMBL17049367 0.79 CCR5 (0.56) CCR5HTTSMN1; SMN2ALDH1A1PTGER1
SCHEMBL4215294 0.79 CDK5 (0.52) AGPAT2PRKACACCNB2CDK1CCNB1
SCHEMBL26621373 0.78 FEN1 (0.53) PRKACAAURKAHSP90AA1ADORA2A
SCHEMBL6669227 0.78 ENPP2 (0.48) PRKACACLK1GSK3BCDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS LG CHEM, LTD. (KR) 2024-05-09 US disclosed
EP-4273140-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR Lg Chem, Ltd. (KR) 2023-11-08 EP disclosed
WO-2022169248-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR 주식회사 엘지화학 2022-08-11 WO disclosed
EP-1412327-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG Biomedical Institute (US) 2004-04-28 EP disclosed
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-11-06 US disclosed
US-20030187007-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-10-02 US disclosed
WO-2002096867-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG BIOMEDICAL INSTITUTE (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS MAP3K20, SBK3, MAPKAPK2 AGPAT2 3098/4885PRKACA 101/4885CCNB2 1762/4885
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease MAP3K20, MAP3K1, MAP3K2 AGPAT2 4075/4885PRKACA 62/4885CCNB2 1399/4885
US-20030187007-A1 Inhibitors of protein kinase for the treatment of disease MAP3K20, MAP3K1, MAP3K2 AGPAT2 4075/4885PRKACA 62/4885CCNB2 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.